Novo says its next-gen obesity drug tops Lilly rival in late-stage study

Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)